期刊文献+

自噬在A549肺腺癌细胞耐厄洛替尼中的作用研究 被引量:1

Research on the role of autophagy in A549′s resistance of erlotinib
下载PDF
导出
摘要 目的探讨自噬在A549肺腺癌细胞耐厄洛替尼中的作用。方法不同水平厄洛替尼处理A549细胞及其获得性耐厄洛替尼细胞(A549/ER)后,细胞免疫荧光和Western blot观察自噬标记蛋白微血管相关蛋白1轻链3-Ⅱ(MAP1-LC3-Ⅱ)的变化;应用自噬抑制剂3-甲基腺嘌呤(3-MA)抑制自噬,流式细胞仪(FCM)检测用药后细胞周期及凋亡率。结果低水平(1、5μmol/L)厄洛替尼作用下两种细胞MAP1-LC3-Ⅱ表达水平较对照组(0.1%DMSO)均升高,高水平(25μmol/L)厄洛替尼作用下A549细胞MAP1-LC3-Ⅱ表达水平较低水平时降低,而A549/ER细胞MAP1-LC3-Ⅱ表达水平较低水平时仍升高。厄洛替尼水平提高至100μmol/L可诱导A549/ER细胞凋亡,3-MA抑制自噬后A549/ER细胞的凋亡率从7.76%上升至18.85%。结论自噬增强了A549/ER的耐厄洛替尼作用,抑制自噬可增强厄洛替尼的抗肿瘤作用。 Objective To investigate the effect of autophagy in A549's resistance of erlotinib. Methods After A549 cells were treated with different levels of erlotinib,autophagy was determined by cell immunofluorescence and protein lever of LC3-Ⅱ was de-termined by Western blot at certain times. And then afer inhibiting autophagy by the pharmacological inhibitor 3-methyladenine(3-MA) ,the cell cycle and apoptosis rate were determined by flow cytometry(FCM). Results Compared to control group (0. 1%DM-SO) ,the protein levers of MAP1-LC3-Ⅱ in both A549 and A549/ER were upregulated at low levels(1,5 μmol/L). The protein le-ver of MAP1-LC3-Ⅱ in A549/ER was still upregulated while the protein lever of LC3-Ⅱ in A549 was downregulated at the high level(25 μmol/L). Moreover,A549/ER's apoptosis induced by erlotinib was enhanced after inhibiting autophagy by 3-MA, the ap-optosis rate rose from 7. 76% to 18.85%. Conclusion Autophagy thus represents a role in A549/ER resistance of erlotinib TKIs and inhibiting autophagy may be an approach to improve the efficacy of erlotinib.
出处 《重庆医学》 CAS CSCD 北大核心 2013年第12期1324-1326,1329,共4页 Chongqing medicine
基金 国家自然科学基金资助项目(81172070) 军队临床高新技术重大项目(2010gxjs070)
关键词 肺肿瘤 自噬 厄洛替尼 细胞凋亡 lung neoplasms autophagy erlotinib apoptosis
  • 相关文献

参考文献16

  • 1Ferlay J . Shin HR,Bray F, et al. Estimates of worldwideburden of cancer in 2008 : GLOBOCAN 2008 [J], Int JCancer,2010,127(12):2893-2917.
  • 2Belani CP,Goss G.Blumenschein G Jr. Recent clinical de-velopments and rationale for combining targeted agents innon-small cell lung cancer ( NSCLC) [J]. Cancer TreatRev,2012,38(3):173-184.
  • 3Jackman D,Pao W,Riely GJ. et al. Clinical definition ofacquired resistance to epidermal growth factor receptortyrosine kinase inhibitors in non-small-cell lung cancer[J]. J Clin Oncol,2010,28(2) :357-360.
  • 4Coates JM, Galante JM. Bold RJ. Cancer therapy beyondapoptosis: autophagy and anoikis as mechanisms of celldeath [J]. J Surg Res,2010,164(2) :301-308.
  • 5Tsuhara K, Fujii S. Esumi H. Autophagy and cancer:dynamism of the metabolism of tumor cells and tissues[J]. Cancer Lett,2009,278(2) : 130-138.
  • 6Altmeyer A,Josset E,Denis JM,et al. The mTOR inhibi-tor RADOOl augments radiation-induced growth inhibitionin a hepatocellular carcinoma cell line by increasing auto-phagy [J].Int J 0ncol,2012,41(4) :1381.
  • 7Mohapatra P,Preet R, Das D. et al. Quinacrine-mediated,autophagy and apoptosis in colon cancer cells is through ap53- and p21-dependent mechanism[J], Oncol Res,2012,20(2/3):81-91.
  • 8Apel A,Herr I,Schwarz H,et al. Blocked autophagy sen-sitizes resistant carcinoma cells to radiation therapy [J].Cancer Res,2008,68(5) : 1485-1494.
  • 9Hoyer-Hansen M, Jaattela M. Autophagy: an emergingtarget for cancer therapy [J]. Autophagy, 2008,4 (5):574-580.
  • 10Lomonaco SL,Finniss S.Xiang C, et al. The induction ofautophagy by gamma-radiation contributes to the radiore-sistance of glioma stem cells [J]. Int J Cancer, 2009,125(3):717-722.

同被引文献18

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J ]. CA Cancer J Clin, 2011, 61(2) : 69-90.
  • 2D'Arcangelo M, Cappuzzo F. Erlotinib in the first-line treatment of non-small-cell lung cancer[ J]. Expert Rev Anticancer Ther, 2013, 13(5) : 523-533.
  • 3Nguyen KS, Neal JW. First-line treatment of EGFR-mutant non-small- cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors[ J]. Biologics, 2012, 6: 337-345.
  • 4Tan BX, Yao WX, Ge J, et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes[J]. Cancer, 2011, 117(22) : 5103- 5111.
  • 5Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer [ J ]. J Clin Oucol, 2010, 28(2) : 357-360.
  • 6GaUagher EJ, LeRoith D. Diabetes, cancer, and mefforrrim: connections of metabolism and cell proliferation[J]. Ann N Y Aead Sei, 2011, 1243 : 54-68.
  • 7Li W, Zhou F, Zhou C. Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients [ J ]. Onto Targets Ther, 2014, 7: 253-261.
  • 8Wang Y, Xia H, Zhuang Z, et aJ. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer [ J ]. Cell Death Dis, 2014, 5: e1227.
  • 9Shen H, Zhu F, Liu J, et al. Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer[ J]. PLoS One, 2014, 9(7) : e103305.
  • 10Fang S, Zeng X, Zhu W, et al. Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by miR-200b contributes to multi-drug resistance of small cell lung cancer[ J]. Exp Mol Pathol, 2014, 96 (3) : 438-444.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部